About this Research Topic
Induced pluripotent stem cells (iPSCs) have the ability to differentiate into a variety of tissues and cell types. They are a promising cell source for cell therapy for damaged skeletal muscle and inherited muscle diseases such as Duchenne muscular dystrophy (DMD). However, current transplantation studies have revealed that the regenerative capacity of iPSCs after injection into recipients is limited and requires further study. In particular, it was found that the use of patient-specific iPSCs for modeling muscle disease is limited because in vitro-induced iPSC-derived multinucleated myofibers are still immature compared to postnatal myofibers, and patients require mature forms of myofibers.
Therefore, it is essential and timely to summarize the progress of research on disease modeling using iPSCs and iPSC-based cell therapy in the field of skeletal muscular diseases. In particular, collecting technical tips for successful induction protocols of iPSC-derived skeletal muscle suitable for regenerative medicine and in vitro iPSC-based disease modeling is critical.
Areas to be covered in this Research Topic may include but are not limited to:
• Organoid and 3D culture of iPSC-derived skeletal muscle cells
• In vitro modeling of skeletal muscle diseases using iPSCs
• iPSCs-mediated high throughput screening of small molecules for drug discovery
• Novel protocols for iPSC-derived skeletal muscle stem cells or progenitor cells
• Purification protocols of iPSC-derived skeletal muscle stem cell or /progenitors for regenerative medicine
• Transplantation protocols of iPSC-derived skeletal muscle stem cells or progenitors
• Evaluation of skeletal muscle histology and function following transplantation of iPSC-derived skeletal muscle stem cells or progenitors
• iPSC-derived skeletal muscle stem cells or progenitors for restoration of volumetric muscle loss (VML), a traumatic massive loss of muscular tissue
We accept different article types including Mini-Reviews, Brief Research Reports and Perspectives. A full list of accepted article types, including descriptions, can be found at this link.
Therefore, it is essential and timely to summarize the progress of research on disease modeling using iPSCs and iPSC-based cell therapy in the field of skeletal muscular diseases. In particular, collecting technical tips for successful induction protocols of iPSC-derived skeletal muscle suitable for regenerative medicine and in vitro iPSC-based disease modeling is critical.
Areas to be covered in this Research Topic may include but are not limited to:
• Organoid and 3D culture of iPSC-derived skeletal muscle cells
• In vitro modeling of skeletal muscle diseases using iPSCs
• iPSCs-mediated high throughput screening of small molecules for drug discovery
• Novel protocols for iPSC-derived skeletal muscle stem cells or progenitor cells
• Purification protocols of iPSC-derived skeletal muscle stem cell or /progenitors for regenerative medicine
• Transplantation protocols of iPSC-derived skeletal muscle stem cells or progenitors
• Evaluation of skeletal muscle histology and function following transplantation of iPSC-derived skeletal muscle stem cells or progenitors
• iPSC-derived skeletal muscle stem cells or progenitors for restoration of volumetric muscle loss (VML), a traumatic massive loss of muscular tissue
We accept different article types including Mini-Reviews, Brief Research Reports and Perspectives. A full list of accepted article types, including descriptions, can be found at this link.
Keywords: skeletal muscle; iPSC; muscle stem cell; satellite cell; myoblast; muscular dystrophy; volumetric muscle loss; muscle regeneration
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
